C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples